MVCD1
MCID: MCR129
MIFTS: 54

Microvascular Complications of Diabetes 1 (MVCD1) malady

Categories: Genetic diseases, Cardiovascular diseases, Eye diseases, Neuronal diseases, Nephrological diseases

Aliases & Classifications for Microvascular Complications of Diabetes 1

Aliases & Descriptions for Microvascular Complications of Diabetes 1:

Name: Microvascular Complications of Diabetes 1 54 66 29 13
Proliferative Diabetic Retinopathy 12 66 52 14 69
Diabetic Nephropathy 66 69
Non-Proliferative Diabetic Retinopathy 66
Nonproliferative Diabetic Retinopathy 69
Complications of Diabetes Mellitus 69
Diabetic End-Stage Renal Disease 66
Diabetes Complications 42
Diabetic Neuropathies 69
Diabetic Neuropathy 66
Mvcd1 66
Pdr 12

Classifications:



External Ids:

OMIM 54 603933
Disease Ontology 12 DOID:13207
ICD9CM 35 362.02
NCIt 47 C84457
SNOMED-CT 64 154679002 59276001
MeSH 42 D048909
UMLS 69 C0154830

Summaries for Microvascular Complications of Diabetes 1

UniProtKB/Swiss-Prot : 66 Microvascular complications of diabetes 1: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 1, also known as proliferative diabetic retinopathy, is related to diabetic neuropathy and microvascular complications of diabetes 1, susceptibility, and has symptoms including neuralgia and sciatica. An important gene associated with Microvascular Complications of Diabetes 1 is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Amlodipine and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include eye, and related phenotypes are cardiovascular system and cellular

Description from OMIM: 603933

Related Diseases for Microvascular Complications of Diabetes 1

Diseases in the Microvascular Complications of Diabetes 1 family:

Microvascular Complications of Diabetes 4 Microvascular Complications of Diabetes 7
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 2
Microvascular Complications of Diabetes 5 Microvascular Complications of Diabetes 3

Diseases related to Microvascular Complications of Diabetes 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 152)
id Related Disease Score Top Affiliating Genes
1 diabetic neuropathy 12.4
2 microvascular complications of diabetes 1, susceptibility 12.2
3 microvascular complications of diabetes 3 11.3
4 background diabetic retinopathy 11.3
5 microvascular complications of diabetes 2 11.3
6 vitreoretinopathy, neovascular inflammatory 11.2
7 microvascular complications of diabetes 7 11.1
8 severe nonproliferative diabetic retinopathy 11.1
9 pigmentary disorder, reticulate, with systemic manifestations 11.0
10 neuropathy 10.9
11 diabetic autonomic neuropathy 10.9
12 retinitis 10.6
13 endotheliitis 10.6
14 retinal detachment 10.4
15 vaginal adenoma 10.3 IGF1 SST
16 bipolar i disorder 10.2 ANGPT2 FGF2 VEGFA
17 cardioauditory syndrome of sanchez cascos 10.2 IGF1 SST VEGFA
18 tooth erosion 10.2 FGF2 SST VEGFA
19 common variable immunodeficiency 10.2 FGF2 HGF VEGFA
20 rheumatic encephalitis 10.2 IGF1 SST VEGFA
21 rickets 10.2 HGF IGF1 SST
22 scar contracture 10.2 CCL2 SERPINF1 VEGFA
23 anterograde amnesia 10.2 FGF2 SERPINF1 VEGFA
24 hyperinsulinism 10.2 ANGPT2 TGFB2 VEGFA
25 hypersensitivity reaction type iii disease 10.2 CXCL8 MMP9
26 neovascular glaucoma 10.2
27 ulcerative proctitis 10.2 CCL2 CXCL8 VEGFA
28 pituitary infarct 10.2 ANGPT2 MMP9 VEGFA
29 nasal cavity cancer 10.1 CXCL8 FGF2 HGF
30 phlegmonous dacryocystitis 10.1 ICAM1 VCAM1 VEGFA
31 exophthalmic ophthalmoplegia 10.1 MMP9 VCAM1 VEGFA
32 localized junctional epidermolysis bullosa, non-herlitz type 10.1 ANGPT2 FLT1 VEGFA
33 neuropathy, hereditary sensory, type ib 10.1 FGF2 MMP9 VEGFA
34 focal dystonia 10.1 CCL2 HGF VCAM1 VEGFA
35 ovarian clear cell malignant adenofibroma 10.1 ICAM1 SST VCAM1
36 vaginal endometrial stromal tumor 10.1 HGF ICAM1 VCAM1
37 venous insufficiency 10.1 FGF2 TGFB2 VEGFA
38 vulvitis 10.1 ANGPT2 FLT1 VEGFA
39 mitral valve stenosis 10.1 FGF2 FLT1 VEGFA
40 chromophobe adenoma 10.1 CXCL8 ICAM1
41 hemorrhagic cystitis 10.1 CCL2 CTGF HGF
42 benign secondary hypertension 10.1 CCL2 ICAM1 VCAM1
43 cutaneous candidiasis 10.1 CCL2 CXCL8 ICAM1
44 kidney osteogenic sarcoma 10.0 FLT1 MMP9 VEGFA
45 erb-duchenne and dejerine-klumpke palsies 10.0 CXCL8 ICAM1 VCAM1
46 spastic hemiplegia 10.0 FGF2 ICAM1 MMP9
47 maxillary neoplasm 10.0 FLT1 MMP9 VEGFA
48 strawberry gallbladder 10.0 CCL2 CXCL8 ICAM1
49 limb ischemia 10.0 CXCL8 ICAM1 IGF1
50 welander distal myopathy 10.0 FLT1 VCAM1 VEGFA

Comorbidity relations with Microvascular Complications of Diabetes 1 via Phenotypic Disease Network (PDN): (show all 24)


Acute Cystitis Acute Kidney Failure
Benign Essential Hypertension Chronic Kidney Failure
Chronic Myocardial Ischemia Decubitus Ulcer
Deficiency Anemia Diabetic Cataract
Diabetic Polyneuropathy Heart Disease
Hypertension, Essential Hypoglycemia
Hypoglycemic Coma Hypothyroidism
Intermediate Coronary Syndrome Iron Deficiency Anemia
Ischemic Heart Disease Kidney Disease
Microvascular Complications of Diabetes 7 Mitral Valve Disease
Neurogenic Arthropathy Peripheral Vascular Disease
Rubeosis Iridis Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 1:



Diseases related to Microvascular Complications of Diabetes 1

Symptoms & Phenotypes for Microvascular Complications of Diabetes 1

Clinical features from OMIM:

603933

UMLS symptoms related to Microvascular Complications of Diabetes 1:


neuralgia, sciatica

MGI Mouse Phenotypes related to Microvascular Complications of Diabetes 1:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.34 FLT1 HGF ICAM1 IGF1 MMP9 SERPINF1
2 cellular MP:0005384 10.29 IGF1 MMP9 TGFB2 VCAM1 VEGFA ANGPT2
3 hematopoietic system MP:0005397 10.2 FGF2 FLT1 HGF ICAM1 IGF1 MMP9
4 growth/size/body region MP:0005378 10.18 CTGF FLT1 HGF ICAM1 IGF1 MMP9
5 immune system MP:0005387 10.18 ANGPT2 CCL2 CXCL12 FLT1 ICAM1 IGF1
6 mortality/aging MP:0010768 10.18 ANGPT2 CTGF CXCL12 FGF2 FLT1 HGF
7 homeostasis/metabolism MP:0005376 10.17 ANGPT2 CTGF FGF2 FLT1 ICAM1 IGF1
8 digestive/alimentary MP:0005381 10.1 ANGPT2 CTGF ICAM1 MMP9 SERPINF1 SST
9 nervous system MP:0003631 9.96 CXCL12 FGF2 FLT1 ICAM1 IGF1 MMP9
10 muscle MP:0005369 9.92 CXCL12 FGF2 FLT1 ICAM1 IGF1 MMP9
11 reproductive system MP:0005389 9.81 IGF1 MMP9 SERPINF1 TGFB2 VCAM1 VEGFA
12 skeleton MP:0005390 9.56 FGF2 IGF1 MMP9 SERPINF1 SST TGFB2
13 vision/eye MP:0005391 9.28 ANGPT2 CTGF FGF2 FLT1 ICAM1 MMP9

Drugs & Therapeutics for Microvascular Complications of Diabetes 1

Drugs for Microvascular Complications of Diabetes 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 909)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amlodipine Approved Phase 4 88150-42-9 2162
2
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
3
Atenolol Approved Phase 4 29122-68-7 2249
4
Clonidine Approved Phase 4,Phase 3,Phase 2 4205-90-7 2803
5
Doxazosin Approved Phase 4 74191-85-8 3157
6
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
7
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2 58-93-5 3639
8
Irbesartan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 138402-11-6 3749
9
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
10
Simvastatin Approved Phase 4,Phase 3,Phase 2 79902-63-9 54454
11
Diazoxide Approved Phase 4,Phase 2,Phase 3 364-98-7 3019
12
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
13
Febuxostat Approved Phase 4 144060-53-7 134018
14
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1 10102-43-9 145068
15
Nitroglycerin Approved, Investigational Phase 4,Phase 2 55-63-0 4510
16
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
17 Moxonidine Approved Phase 4 75438-57-2 4810
18
Spironolactone Approved Phase 4,Phase 2,Phase 3,Phase 1 1952-01-7, 52-01-7 5833
19
Fenofibrate Approved Phase 4,Phase 3 49562-28-9 3339
20
Ticlopidine Approved Phase 4,Phase 2,Phase 3 55142-85-3 5472
21
Acarbose Approved, Investigational Phase 4,Phase 3,Early Phase 1 56180-94-0 441184
22
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
23
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 148553-50-8 5486971
24
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
25
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2 13422-51-0 11953898 5460373 44475014
26
Glatiramer Acetate Approved, Investigational Phase 4 147245-92-9 3081884
27
Mannitol Approved, Investigational Phase 4,Phase 1,Phase 2 69-65-8 453 6251
28
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613 2171
29
Aztreonam Approved Phase 4,Phase 2 78110-38-0 5362041 5742832
30
Clindamycin Approved, Vet_approved Phase 4,Phase 2 18323-44-9 29029
31
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 100986-85-4 149096
32
Linezolid Approved, Investigational Phase 4,Phase 2 165800-03-3 441401
33
Metronidazole Approved Phase 4,Phase 2,Phase 3,Early Phase 1 443-48-1 4173
34
Ofloxacin Approved Phase 4,Phase 3,Phase 2 82419-36-1 4583
35
Piperacillin Approved Phase 4,Phase 3,Phase 2 66258-76-2 43672
36
Tazobactam Approved Phase 4,Phase 3,Phase 2 89786-04-9 123630
37
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
38
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
39
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
40
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
41
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 128794-94-5 5281078
42
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24280-93-1 446541
43
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
44
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 104987-11-3 445643 439492
45
Sertraline Approved Phase 4 79617-96-2 68617
46
Isosorbide Dinitrate Approved Phase 4,Phase 3 87-33-2 6883
47
Methyltestosterone Approved Phase 4,Phase 2 58-18-4 6010
48
Testosterone Approved, Investigational Phase 4,Phase 2 58-22-0 6013
49
Cilostazol Approved Phase 4,Phase 3 73963-72-1 2754
50
Menthol Approved Phase 4,Phase 2,Phase 3,Phase 1 2216-51-5 16666

Interventional clinical trials:

(show top 50) (show all 2881)
id Name Status NCT ID Phase
1 Nephropathy In Type 2 Diabetes and Cardio-renal Events Unknown status NCT00535925 Phase 4
2 Use of Diazoxide in Acute Hypoglycaemia Unknown status NCT01488136 Phase 4
3 Ranibizumab in Diabetic Vitrectomy Unknown status NCT01306981 Phase 4
4 The Effect of Uric Acid Lowering in Type 1 Diabetes Unknown status NCT02344602 Phase 4
5 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study) Unknown status NCT01869881 Phase 4
6 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease Unknown status NCT01094769 Phase 4
7 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4
8 Aldosterone in Diabetic Nephropathy Unknown status NCT00870402 Phase 4
9 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
10 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy Unknown status NCT00123136 Phase 4
11 HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study) Unknown status NCT00106886 Phase 4
12 Effects of Fenofibrate on Endothelial Progenitor Cells in Diabetes Unknown status NCT01927315 Phase 4
13 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4
14 Effect of Sulodexide on Albuminuria in Chinese Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4
15 Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4
16 Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
17 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4
18 Inspiratory Muscle Training in Patients With Autonomic Neuropathic Unknown status NCT00752440 Phase 4
19 Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy Unknown status NCT01770964 Phase 4
20 PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy Unknown status NCT02005432 Phase 4
21 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4
22 Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED) Unknown status NCT01486771 Phase 4
23 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
24 Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation Unknown status NCT00677664 Phase 4
25 Changes in Macular Thickness After Patterns Scan Laser Unknown status NCT00563628 Phase 4
26 Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment Unknown status NCT00563043 Phase 4
27 Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage Unknown status NCT01824043 Phase 4
28 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4
29 Efficacy and Safety of Garamycin® Sponge (Gentamicin-Collagen Sponge) in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection Unknown status NCT01951768 Phase 4
30 Clinical Evaluation of the SNaP Wound Care System Unknown status NCT01113658 Phase 4
31 Organization Program of DiabEtes INsulIN ManaGement Unknown status NCT01338376 Phase 4
32 Metformin and Gestational Diabetes in High-risk Patients: a RCTs Unknown status NCT00883259 Phase 4
33 Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients Unknown status NCT02036554 Phase 4
34 Multifactorial Intervention in Type 2 Diabetes - Italy Unknown status NCT01240070 Phase 4
35 Diabetes and Depression in Hispanics and African Americans: Treatment of Depression With Sertraline and Its Effect on A1c and Quality of Life Unknown status NCT00624013 Phase 4
36 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
37 Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes Unknown status NCT01978405 Phase 4
38 Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes Unknown status NCT02236481 Phase 4
39 Curcumin Therapy in Patients With Impaired Glucose Tolerance and Insulin Resistance Unknown status NCT01052025 Phase 4
40 Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism Unknown status NCT01084369 Phase 4
41 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4
42 Curcumin for Type 2 Diabetic Patients Unknown status NCT01052597 Phase 4
43 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4
44 Metronidazole and Amoxicillin for the Treatment of Type 2 Diabetic Subjects With Periodontitis Unknown status NCT02135952 Phase 4
45 Effectiveness of Metformin in Recurrent Miscarriage in a Woman With Hyperinsulinaemia Unknown status NCT01718340 Phase 4
46 Obtain a Good Blood Glucose Control With the Paradigm Real Time System Unknown status NCT00441129 Phase 4
47 Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events Unknown status NCT00886574 Phase 4
48 Prevention of Diabetes Mellitus Development in Women Who Had Already Experienced A Gestational Diabetes Unknown status NCT00265746 Phase 4
49 Rajavithi Health Promotion Project (Population Base Cohort) Unknown status NCT00368095 Phase 4
50 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4

Search NIH Clinical Center for Microvascular Complications of Diabetes 1

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: diabetes complications

Genetic Tests for Microvascular Complications of Diabetes 1

Genetic tests related to Microvascular Complications of Diabetes 1:

id Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes 1 29

Anatomical Context for Microvascular Complications of Diabetes 1

MalaCards organs/tissues related to Microvascular Complications of Diabetes 1:

39
Eye

Publications for Microvascular Complications of Diabetes 1

Variations for Microvascular Complications of Diabetes 1

ClinVar genetic disease variations for Microvascular Complications of Diabetes 1:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 VEGFA NM_001025366.2(VEGFA): c.-94C> G single nucleotide variant risk factor rs2010963 GRCh37 Chromosome 6, 43738350: 43738350

Expression for Microvascular Complications of Diabetes 1

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 1.

Pathways for Microvascular Complications of Diabetes 1

Pathways related to Microvascular Complications of Diabetes 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 CTGF CXCL12 FGF2 FLT1 HGF IGF1
2
Show member pathways
13.84 ANGPT2 CCL2 CTGF CXCL12 CXCL8 FGF2
3
Show member pathways
13.72 CTGF CXCL12 FGF2 FLT1 HGF IGF1
4
Show member pathways
13.66 ANGPT2 CCL2 CXCL12 CXCL8 FLT1 HGF
5
Show member pathways
13.42 CCL2 CXCL12 CXCL8 ICAM1 MMP9 TGFB2
6
Show member pathways
13.42 ANGPT2 CCL2 CTGF CXCL12 CXCL8 FGF2
7
Show member pathways
13.39 ANGPT2 CCL2 CTGF CXCL12 CXCL8 FGF2
8
Show member pathways
13.37 CCL2 CXCL8 FGF2 HGF ICAM1 MMP9
9
Show member pathways
13.33 CTGF CXCL12 FGF2 FLT1 HGF IGF1
10
Show member pathways
13.27 CTGF CXCL12 FGF2 FLT1 HGF IGF1
11
Show member pathways
13.24 ANGPT2 CCL2 CTGF CXCL12 CXCL8 FGF2
12
Show member pathways
13.07 CTGF CXCL12 FGF2 FLT1 HGF IGF1
13
Show member pathways
13.03 FGF2 FLT1 HGF IGF1 MMP9 VEGFA
14
Show member pathways
12.99 CCL2 CTGF CXCL12 FGF2 FLT1 HGF
15
Show member pathways
12.76 FGF2 ICAM1 MMP9 TGFB2 VCAM1
16
Show member pathways
12.75 ANGPT2 FGF2 FLT1 HGF IGF1 VEGFA
17
Show member pathways
12.72 CTGF CXCL12 FGF2 FLT1 HGF IGF1
18
Show member pathways
12.68 CCL2 CXCL12 ICAM1 MMP9 VCAM1 VEGFA
19 12.63 CXCL12 CXCL8 FGF2 HGF IGF1 MMP9
20 12.61 ANGPT2 FGF2 FLT1 HGF IGF1 VEGFA
21
Show member pathways
12.41 CCL2 ICAM1 VCAM1 VEGFA
22 12.32 FGF2 HGF IGF1 MMP9 TGFB2 VEGFA
23 12.25 CXCL8 FLT1 IGF1 MMP9
24 12.12 CCL2 ICAM1 MMP9 VCAM1 VEGFA
25 12.09 FGF2 HGF IGF1 VCAM1 VEGFA
26 12.05 CCL2 CXCL8 ICAM1 MMP9
27 12 CCL2 ICAM1 MMP9 VCAM1
28 11.95 ANGPT2 FLT1 IGF1 VEGFA
29 11.94 ICAM1 MMP9 VCAM1
30 11.93 FGF2 IGF1 TGFB2 VCAM1
31 11.92 CXCL12 CXCL8 ICAM1 VCAM1
32 11.84 CCL2 CXCL8 ICAM1 TGFB2 VCAM1 VEGFA
33
Show member pathways
11.81 CXCL12 CXCL8 VCAM1
34 11.79 FGF2 IGF1 VEGFA
35 11.76 CTGF CXCL12 FGF2 HGF IGF1 TGFB2
36 11.76 CCL2 CXCL12 CXCL8 FLT1 ICAM1 TGFB2
37 11.75 CXCL8 MMP9 VEGFA
38 11.73 ICAM1 TGFB2 VCAM1
39 11.72 FGF2 IGF1 MMP9 TGFB2 VEGFA
40
Show member pathways
11.69 CXCL8 ICAM1 MMP9 VCAM1 VEGFA
41 11.67 CXCL8 IGF1 MMP9
42 11.64 ANGPT2 CCL2 FGF2 FLT1 HGF MMP9
43 11.57 FGF2 HGF IGF1 VEGFA
44 11.56 FGF2 TGFB2 VEGFA
45 11.56 CCL2 CXCL8 ICAM1
46 11.54 CTGF ICAM1 MMP9
47 11.5 CXCL8 ICAM1 VCAM1
48 11.49 CCL2 CXCL8 HGF ICAM1 TGFB2 VCAM1
49 11.39 CCL2 CXCL8 MMP9
50 11.34 CXCL12 FGF2 MMP9

GO Terms for Microvascular Complications of Diabetes 1

Cellular components related to Microvascular Complications of Diabetes 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 ANGPT2 CCL2 CTGF CXCL12 CXCL8 FGF2
2 extracellular space GO:0005615 9.53 ANGPT2 CCL2 CTGF CXCL12 CXCL8 FGF2
3 platelet alpha granule lumen GO:0031093 9.46 HGF IGF1 TGFB2 VEGFA

Biological processes related to Microvascular Complications of Diabetes 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
id Name GO ID Score Top Affiliating Genes
1 extracellular matrix organization GO:0030198 9.95 FGF2 ICAM1 MMP9 TGFB2 VCAM1
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.93 CCL2 CTGF FGF2 ICAM1
3 aging GO:0007568 9.92 CCL2 CTGF SERPINF1 VCAM1
4 phosphatidylinositol-mediated signaling GO:0048015 9.89 FGF2 HGF IGF1
5 activation of MAPK activity GO:0000187 9.88 FGF2 HGF IGF1
6 platelet degranulation GO:0002576 9.88 HGF IGF1 TGFB2 VEGFA
7 cellular response to tumor necrosis factor GO:0071356 9.88 CCL2 CXCL8 ICAM1 VCAM1
8 chemotaxis GO:0006935 9.88 CCL2 CXCL12 CXCL8 FGF2 FLT1
9 kidney development GO:0001822 9.87 SERPINF1 TGFB2 VEGFA
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.86 HGF ICAM1 IGF1 VEGFA
11 positive regulation of cell proliferation GO:0008284 9.86 CTGF CXCL12 FGF2 FLT1 HGF IGF1
12 response to wounding GO:0009611 9.85 CCL2 CTGF TGFB2
13 cellular response to interleukin-1 GO:0071347 9.85 CCL2 CXCL8 ICAM1
14 chemokine-mediated signaling pathway GO:0070098 9.84 CCL2 CXCL12 CXCL8
15 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.84 CCL2 FLT1 VEGFA
16 positive regulation of endothelial cell proliferation GO:0001938 9.84 CCL2 CXCL12 FGF2 VEGFA
17 response to mechanical stimulus GO:0009612 9.83 ANGPT2 CCL2 CXCL12
18 neutrophil chemotaxis GO:0030593 9.83 CCL2 CXCL8 TGFB2
19 negative regulation of angiogenesis GO:0016525 9.83 ANGPT2 CCL2 SERPINF1
20 positive regulation of MAP kinase activity GO:0043406 9.81 FGF2 FLT1 VEGFA
21 cellular response to glucose stimulus GO:0071333 9.81 CCL2 ICAM1 SERPINF1
22 cell chemotaxis GO:0060326 9.81 CCL2 CXCL12 HGF VCAM1
23 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.8 FLT1 HGF IGF1 TGFB2
24 positive regulation of cell migration GO:0030335 9.8 CXCL12 FLT1 HGF IGF1 MMP9 VEGFA
25 positive regulation of cell adhesion GO:0045785 9.79 CCL2 CXCL12 VEGFA
26 positive regulation of cell division GO:0051781 9.78 FGF2 TGFB2 VEGFA
27 cellular response to dexamethasone stimulus GO:0071549 9.77 CCL2 ICAM1 SERPINF1
28 response to heat GO:0009408 9.76 CCL2 CXCL12 IGF1 SST
29 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.74 FLT1 VCAM1 VEGFA
30 animal organ regeneration GO:0031100 9.73 ANGPT2 CCL2 CXCL12 HGF
31 positive regulation of calcium ion import GO:0090280 9.72 CCL2 CXCL12
32 negative regulation of release of cytochrome c from mitochondria GO:0090201 9.72 HGF IGF1
33 macrophage differentiation GO:0030225 9.71 MMP9 VEGFA
34 embryonic morphogenesis GO:0048598 9.71 FGF2 FLT1
35 response to amino acid GO:0043200 9.71 CCL2 CTGF ICAM1 SST
36 cell migration involved in sprouting angiogenesis GO:0002042 9.7 FGF2 VEGFA
37 negative regulation of blood vessel endothelial cell migration GO:0043537 9.7 ANGPT2 FGF2
38 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.7 FLT1 VEGFA
39 induction of positive chemotaxis GO:0050930 9.7 CXCL12 CXCL8 VEGFA
40 positive regulation of leukocyte migration GO:0002687 9.69 CCL2 VEGFA
41 glial cell migration GO:0008347 9.69 CCL2 TGFB2
42 PERK-mediated unfolded protein response GO:0036499 9.68 CCL2 CXCL8
43 response to acidic pH GO:0010447 9.68 SERPINF1 SST
44 chronic inflammatory response GO:0002544 9.68 CCL2 VCAM1
45 positive regulation of phospholipase C activity GO:0010863 9.67 FGF2 FLT1
46 positive chemotaxis GO:0050918 9.67 CXCL12 FGF2 HGF VEGFA
47 positive regulation of axon extension involved in axon guidance GO:0048842 9.65 CXCL12 VEGFA
48 positive regulation of cellular extravasation GO:0002693 9.64 CCL2 ICAM1
49 positive regulation of angiogenesis GO:0045766 9.63 ANGPT2 CXCL8 FGF2 FLT1 HGF VEGFA
50 membrane to membrane docking GO:0022614 9.62 ICAM1 VCAM1

Molecular functions related to Microvascular Complications of Diabetes 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.63 CCL2 CXCL12 CXCL8